تجاوز إلى المحتوى الرئيسي
User Image

Shaun Sabico

Assistant Professor

Assistant Professor and Deputy Director

كلية العلوم
Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, KSU
المنشورات
مقال فى مجلة
2017

Effects of a multi-strain probiotic supplement for 12 weeks in circulating endotoxin levels and cardiometabolic profiles of medication naïve T2DM patients: a randomized clinical trial

BACKGROUND:

The present randomized clinical trial characterized the beneficial effects of a multi-strain probiotics supplementation on improving circulating endotoxin levels (primary endpoint) and other cardiometabolic biomarkers (secondary endpoint) in patients with T2DM.

METHODS:

A total of 78 adult Saudi T2DM patients (naïve and without co-morbidities) participated in this clinical trial and were randomized to receive twice daily placebo or probiotics [(2.5 × 109 cfu/g) containing the following bacterial strains: Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19 and Lactococcus lactis W58 (Ecologic®Barrier)] in a double-blind manner for 12 weeks. Anthropometrics and cardiometabolic profiles were obtained at baseline and after 12/13 weeks of treatment.

RESULTS:

After 12/13 weeks of intervention and using intention-to-treat analysis, no difference was noted in endotoxin levels between groups [Placebo - 9.5% vs. Probiotics - 52.2%; (CI - 0.05 to 0.36; p = 0.15)]. Compared with the placebo group however, participants in the probiotics groups had a significant but modest improvement in WHR [Placebo 0.0% vs. Probiotics 1.11%; (CI - 0.12 to - 0.01; p = 0.02)] as well as a clinically significant improvement in HOMA-IR [Placebo - 12.2% vs. Probiotics - 60.4%; (CI - 0.34 to - 0.01; p = 0.04)].

CONCLUSION:

Using a multi-strain probiotic supplement daily for 12/13 weeks significantly improved HOMA-IR and modestly reduced abdominal adiposity among medication naïve T2DM patients.

TRIAL REGISTRATION:

ClinicalTrials.gov Identifier: NCT01765517 , Registered January 10, 2013.

نوع عمل المنشور
Randomized Clinical Trial
رقم المجلد
15
رقم الانشاء
1
مجلة/صحيفة
Journal of Translational Medicine 2017
الصفحات
249
مزيد من المنشورات
publications

Hyperglycemia associated with prediabetes (PD) alters NLRP3 inflammasome activity and related interleukins, yet no study has evaluated the expression of the NLRP3 inflammasome complex and related…

بواسطة Alfadul H, Sabico S, Alnaami AM, Amer OE, Hussain SD, Wani K, Clerici M, Al-Daghri NM
2023
تم النشر فى:
MDPI
publications

Objectives

بواسطة Aljuraiban GS, Algabsani S, Sabico S, Alshammari S, Aljazairy E, Al-Musharaf S
2023
تم النشر فى:
Elsevier
publications

The Metabolically Healthy Obese (MHO) is a unique phenotype of obesity in which individuals match the operational definition of obesity but do not display metabolic complications. Given this…

بواسطة Kaiser Wani , Balvir Kumar , Iram Saba , Shaun Sabico
2023
تم النشر فى:
Biolife Sas